Apoptosis repressor with caspase recruitment domain (ARC)

Apoptosis repressor with caspase recruitment domain (ARC), encoded by the NOL3 gene, is a potent multifunctional inhibitor of programmed cell death uniquely characterized by its ability to suppress both the intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways (UniProt P50402). It functions by physically interacting with and inhibiting pro-apoptotic proteins such as caspase-8, caspase-2, and BAX, thereby preventing the activation of the caspase cascade (PubMed: 10455128). While ARC is primarily expressed in terminally differentiated cells like cardiomyocytes and skeletal muscle where it provides essential protection against ischemia-induced death, its aberrant overexpression is frequently observed in various human cancers, contributing to chemoresistance and tumor progression (PubMed: 15743820). Consequently, ARC is considered a significant therapeutic target; inhibiting its activity in oncology could sensitize resistant tumors to treatment, whereas enhancing its function in the heart may offer a strategy to mitigate damage from myocardial infarction or heart failure (PubMed: 21536911).

Other names

Nucleolar protein 3NOL3Muscle-specific aurora aurora-binding proteinMYPNOP30

Currently, there are no FDA-approved drugs specifically targeting ARC; however, experimental strategies focus on small molecule inhibitors to sensitize cancer cells to apoptosis or gene therapy to overexpress ARC for cardioprotection.